Vivani Medical VANI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Income Loss by Business | ||||||
| Biopharm Division | -$6.01M+3.1% | -$6.2M-5.1% | -$5.9M+7.8% | -$6.4M-13.4% | -$5.65M-2.0% | |
| Neuromodulation Division | -$768K— | —— | -$700K+12.5% | -$800K-14.3% | -$700K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vivani Medical break its business down?
- Vivani Medical (VANI) reports net income loss by business across 3 parts — Biopharm Division, Neuromodulation Division and Neurostimulation Division. Each is extracted from the segment footnotes and tracked over time.
- Where does Vivani Medical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vivani Medical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.